ÂÜÀòÂÒÂ×

Michelle LeBlanc has a wealth of experience in the field of in vivo biology. Michelle began their career in 2010 as an MS Graduate Student at the University of Miami, Miller School of Medicine, where they critically analyzed the efficacy of AAV viral and LV based vector systems for therapeutic growth factor delivery. Michelle then moved on to become a PhD Graduate Student at the same institution, where they systematized and validated a high-throughput in vivo screening technology for novel drug targets using NGS technology. In 2016, they became a Postdoctoral Research Fellow at Harvard Medical School, where they worked as a molecular and vascular biologist for over 7 years, using in vitro and in vivo model systems to identify targets for ocular disease. In 2019, they joined Generation Bio as an Associate Director, Senior Scientist, and Scientist. Most recently, in 2022, they became the Director of In Vivo Biology at SalioGen Therapeutics.

Michelle LeBlanc obtained a Bachelor of Science (B.S.) in Biology, General from Syracuse University between 2005 and 2009. Michelle then went on to obtain a Master's Degree in Biological and Biomedical Sciences from Barry University between 2010 and 2012. Finally, they received their Doctor of Philosophy (Ph.D.) in Molecular and Cellular Pharmacology from the University of Miami Miller School of Medicine between 2012 and 2016.